ArticleBMC oral health2026
Combining waterlase ablation and submucosal ALA injection to enhance photodynamic therapy in early-stage oral squamous cell carcinoma: a three-patient case series.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Oral squamous cell carcinoma (OSCC), a common type of oral cancer, has traditionally relied on surgery or radiotherapy as the main treatment. However, these treatments often put patients at risk of deformity and speech dysfunction due to the special anatomical location of the tongue. Local 5-aminolevulinic acid photodynamic therapy (ALA-PDT) is an effective and non-invasive in situ treatment method that can treat tumors while preserving normal tissue morphology and structure. Nevertheless, the curative effect of ALA-PDT is constrained by the permeability of the photosensitizer and the penetration depth of the therapeutic laser source. This study reports three cases of early-stage well-differentiated OSCC that were managed with a nonsurgical approach. In an attempt to enhance the therapeutic effectiveness of ALA-PDT, we employed Waterlase technology to perform abrasion on the lesioned area, with the dual goals of eliminating local hyperplasia and white lesions and facilitating deeper penetration of the laser light source. Immediately following this, these patients underwent local puncture-like injections of 20% ALA. By means of this procedure, the interference caused by the epithelium on the penetration of ALA could be directly avoided. Upon completion of a 2 h incubation period, PDT was initiated at a dose of 119.4 J/cm². Before and after treatment, we evaluated the treatment effect by artificial intelligence (AI)-assisted deoxyribo nucleic acid (DNA) aneuploidy cytology by image cytometry (DNA-ICM). After 6 months of follow-up observation, these patients showed no signs of tumor recurrence. This preliminary case series suggests that Waterlase ablation-assisted submucosal ALA-PDT may provide a potential treatment alternative for early-stage OSCC. Notably, it particularly shines in the aspects of maintaining the patient’s normal physiological functions and elevating the quality of life.All patients provided linguistically appropriate written informed consent after receiving detailed information about ALA-PDT’s therapeutic mechanisms, recurrence risks, and alternative therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.